GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metacrine Inc (OTCPK:MTCR) » Definitions » Tax Expense

Metacrine (Metacrine) Tax Expense : $0.00 Mil (TTM As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Metacrine Tax Expense?

Metacrine's tax expense for the months ended in Sep. 2022 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00 Mil.


Metacrine Tax Expense Historical Data

The historical data trend for Metacrine's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metacrine Tax Expense Chart

Metacrine Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Tax Expense
- - - -

Metacrine Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Metacrine Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Metacrine  (OTCPK:MTCR) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Metacrine Tax Expense Related Terms

Thank you for viewing the detailed overview of Metacrine's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Metacrine (Metacrine) Business Description

Traded in Other Exchanges
N/A
Address
3985 Sorrento Valley Boulevard, Suite C, San Diego, CA, USA, 92121
Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.
Executives
Michael York officer: Chief Business Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Preston Klassen director, officer: President & CEO 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett 10 percent owner
Scott D Sandell 10 percent owner
Venbio Global Strategic Fund, L.p. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Hubert C Chen officer: Chief Medical Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Julia C. Owens director C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451